Every Form 4 that MetLife, Inc. (MET) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MET and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MET filings page.
MetLife Inc. director Jeh C. Johnson was awarded 544 shares of common stock on October 1, 2026, at a reported price of $94.35 per share. His directly held position after the award was 10,101 shares.
MetLife Inc. director Robert Glenn Hubbard acquired 941 shares of common stock on October 1, 2026, at $94.35 per share under the company’s non-management director compensation arrangements. He elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors; his direct holdings after the transaction were 109,132 shares.
MetLife Inc. director Christian Stephane Mumenthaler acquired 544 common shares on October 1, 2026; the reported price was $94.35 per share. The shares were part of non-management director retainer compensation, and Mumenthaler elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. His directly held common stock position after the transaction was 4,018 shares.
MetLife Inc. director Carla A. Harris acquired 544 shares of common stock on October 1, 2026, at a reported $94.35 per share, bringing her directly held position to 11,701 shares. The shares were part of non-management director retainer fees paid in stock; Harris elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Mark A. Weinberger acquired 544 shares of common stock on October 1, 2026, as a grant under compensation arrangements that pay a portion of non-management director retainer fees in common stock. His directly held position after the award was 19,932 shares.
MetLife, Inc. director Diana McKenzie acquired 544 shares of common stock on October 1, 2026, as a portion of non-management director retainer fees paid in common stock. The reported price was $94.35 per share, and her direct holdings after the transaction were 25,929 shares. McKenzie elected to defer receipt of the shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Michelle Seitz acquired 544 common shares on October 1, 2026, in a director compensation award. MetLife’s non-management director compensation arrangements pay a portion of retainer fees in common stock. Seitz directly held 2,125 shares after the acquisition; the reported price per share was $0.0000.
MetLife, Inc. director Laura J. Hay acquired 544 shares of common stock on October 1, 2026, as a compensation award. The reported per-share amount was $94.35, and her reported direct holdings after the award were 6,901 shares. The shares represented a portion of non-management director retainer fees paid in common stock; Hay elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Daniel S. Glaser acquired 544 shares of common stock as compensation on October 1, 2026; the reported per-share amount was $94.35. The shares were part of director retainer fees paid in stock, and Glaser elected to defer their receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. After the award, he reported 3,249 directly held shares and 198 shares held indirectly in a GRAT.
MetLife, Inc. director William E. Kennard acquired 544 common shares on October 1, 2026, as part of non-management director retainer fees paid in stock; the reported transaction price was $94.35 per share. Kennard elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors. His reported direct holdings following the award were 48,248 shares. A separate holding entry lists 10 shares held by the MetLife Policyholder Trust for allocation to eligible policyholders.
METLIFE INC (MET) reported that Ramy Tadros, President, U.S. Business, acquired 115 shares of common stock on September 8, 2026 through a grant/award transaction. The shares reflect imputed reinvestment of dividends on deferred shares under the MetLife Leadership Deferred Compensation Plan, bringing his directly held common shares to 212,695.
METLIFE INC (MET) reported that director William E. Kennard acquired 294 shares of common stock on September 8, 2026 as a grant related to imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference value of $95.50 per share. Following this award, he holds 47,704 shares directly and 10 shares indirectly through the MetLife Policyholder Trust.
METLIFE INC (MET) reported that director Christian Stephane Mumenthaler acquired 21 shares of common stock on September 8, 2026 through a grant classified as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he holds 3,474 shares directly. No Rule 10b5-1 trading plan is reported.
METLIFE INC (MET) reported that director Laura J. Hay acquired 39 shares of common stock on September 8, 2026 at an imputed price of $95.50 per share. The acquisition reflects imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, bringing her direct holdings to 6,357 shares.
METLIFE INC (MET) reported that director Carla A. Harris acquired 42 shares of common stock on September 8, 2026 through a grant/award transaction. The shares reflect imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors, bringing her direct holdings to 11,157 shares.
METLIFE INC (MET) director Robert Glenn Hubbard reported an acquisition of company common stock on September 8, 2026. He received 618 shares at an imputed price of $95.50 per share through reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, bringing his directly held stake to 108,191 shares. The transaction was a compensation-related grant/award acquisition, and no Rule 10b5-1 trading plan is reported.
METLIFE INC (MET) director Jeh C. Johnson reported the acquisition of 59 shares of common stock on September 8, 2026 as a grant/award under a non-derivative transaction. The shares were credited at an imputed value of $95.50 per share through reinvested dividends on deferred shares.
Following this imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors, Johnson now holds 9,557 shares of MetLife common stock in direct ownership, representing deferred shares that have become payable but whose receipt he has elected to defer. No Rule 10b5‑1 trading plan is reported for this transaction.
METLIFE INC (MET) director Diana McKenzie reported an acquisition of company common stock tied to director compensation. On September 8, 2026, she received 157 shares of common stock at an imputed price of $95.50 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this award, she directly holds 25,385 shares of MetLife common stock. No Rule 10b5-1 trading plan is reported for this transaction.
METLIFE INC (MET) reported that director Daniel S. Glaser acquired 10 shares of common stock on September 8, 2026 through an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference value of $95.50 per share. Following this grant, he holds 2,705 shares directly and an additional 198 shares indirectly through a GRAT.
METLIFE INC (MET) reported that executive vice president Bill Pappas had 4,030 shares of common stock withheld on August 31, 2026 at $95.17 per share to pay tax liabilities on shares issued for restricted stock units. After this withholding, he holds 79,716 shares directly, plus 10,220 shares indirectly through a 2024 GRAT and 18,750 shares indirectly through a 2025 GRAT.
METLIFE INC (MET) reported that EVP & Chief Financial Officer John D. McCallion had 6,057 shares of common stock withheld on August 31, 2026 to pay tax liabilities related to vested restricted stock units at a price of $95.17 per share. Following this withholding, he directly holds 269,137 shares of MET common stock; no Rule 10b5-1 trading plan is reported.
METLIFE INC (MET) reported an insider transaction by EVP & Chief Risk Officer Marlene Debel on August 31, 2026. Debel had 4,030 shares of Common Stock withheld to pay tax liabilities on shares issued from restricted stock units, at a reference price of $95.17 per share. This was not an open-market sale but a tax-withholding disposition, and Debel held 150,350 shares of MetLife common stock directly after the transaction. No Rule 10b5-1 trading plan is reported for this filing.
METLIFE INC (MET) reported that Ramy Tadros, President, U.S. Business, had 4,366 shares of common stock disposed of on August 31, 2026 to satisfy tax obligations on recently vested restricted stock units. The shares were withheld by the company for tax payment, and he directly holds 212,580 shares afterward.
MetLife Inc director Christian Stephane Mumenthaler received an award of 587 shares of MetLife common stock on June 16, 2026, valued at $87.40 per share. This grant is part of non-management director retainer fees and was elected to be deferred under MetLife’s Deferred Compensation Plan for Non-Management Directors.
Following this compensation-related acquisition, Mumenthaler directly holds 3,452 shares of MetLife common stock credited to his account.
Kennard William E reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director William E. Kennard received a grant of 587 shares of common stock as non-management director compensation. The award was valued at $87.40 per share and increased his direct holdings to 47,410 shares. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. The filing also shows 10 shares of common stock held indirectly through the MetLife Policyholder Trust.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 587 shares of MetLife common stock on June 16, 2026 as a grant or award. These shares represent a portion of his non-management director retainer that is paid in stock and deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, he directly holds 9,498 shares.
MetLife Inc. director Diana McKenzie reported an acquisition of common stock as part of non-management director compensation. She received a grant of 587 shares valued at $87.40 per share, increasing her direct holdings to 25,229 shares after the transaction. A portion of her director retainer is paid in MetLife stock, and she elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, indicating this is a compensation-related, non–open-market transaction.
Hay Laura J reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Laura J. Hay received an award of 587 shares of MetLife common stock as part of non-management director compensation. The shares were valued at $87.40 per share on the grant date. Following this award, Hay directly holds 6,318 shares of MetLife common stock. According to the disclosure, she elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning the grant is part of standard board retainer fees rather than an open-market purchase.
HUBBARD ROBERT GLENN reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Robert Glenn Hubbard received an equity grant of 1,016 shares of common stock, valued at $87.40 per share, as part of non-management director retainer compensation. He elected to defer receipt of these shares under MetLife’s Deferred Compensation Plan for Non-Management Directors, and now holds 107,573 common shares directly after this award.
Harris Carla A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carla A. Harris received a grant of 587 shares of MetLife common stock at a value of $87.40 per share as part of non-management director compensation. Following this award, she directly holds 11,115 common shares. She elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, meaning the award is compensation-related rather than an open-market purchase.
Seitz Michelle reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Michelle Seitz received a grant of 587 shares of common stock as part of her non-management director compensation. The shares were awarded at no cash cost to her, reflecting retainer fees paid in stock rather than cash. Following this grant, she holds 1,581 MetLife common shares directly.
Glaser Daniel S reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Daniel S. Glaser reported a stock-based compensation award of 587 shares of MetLife common stock, valued at $87.40 per share. This award is part of non-management director retainer fees that are paid in MetLife common stock.
After this grant, Glaser directly holds 2,695 MetLife common shares. He also has an additional 198 shares held indirectly through a grantor retained annuity trust (GRAT). The director elected to defer receipt of the awarded shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
MetLife Inc. director Mark A. Weinberger acquired 587 shares of common stock on June 16, 2026 through a grant tied to non-management director retainer fees, rather than a cash purchase. After this award, he directly holds 19,388 MetLife common shares.
MetLife Inc. director Diana McKenzie reported an automatic share award linked to deferred compensation. She acquired 169 shares of common stock at an imputed price of $85.57 per share through reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this routine compensation-related acquisition, she holds 24,642 shares of MetLife common stock directly.
MetLife Inc. director William E. Kennard reported an additional grant-related acquisition of common stock. On June 9, 2026, he acquired 322 shares of MetLife common stock at $85.57 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he holds 46,823 common shares directly. The filing also notes 10 common shares held indirectly in the MetLife Policyholder Trust established for eligible policyholders.
MetLife Inc. director Laura J. Hay reported an acquisition of 39 shares of MetLife common stock on a Form 4. The shares were credited at a reference price of $85.57 per share through imputed dividend reinvestment under the MetLife Deferred Compensation Plan for Non-Management Directors, rather than an open-market purchase. Following this routine compensation-related award, Hay directly holds 5,731 MetLife common shares.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 61 shares of MetLife common stock through an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors at a reference price of $85.57 per share.
Following this award-related transaction, Johnson directly holds 8,911 shares of MetLife common stock. The filing reflects a routine, compensation-linked increase in his equity position rather than an open-market purchase.
MetLife Inc. director Carla A. Harris reported a small stock-based compensation increase. On the reported date, she acquired 42 shares of MetLife common stock at $85.57 per share through imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this award, she directly holds 10,528 common shares.
MetLife Inc. director Christian Stephane Mumenthaler reported an acquisition of 20 shares of MetLife common stock on a grant/award basis at $85.57 per share. The footnote explains this was an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this transaction, he directly holds 2,865 shares of MetLife common stock.
MetLife director Daniel S. Glaser reported a small share award. On June 9, 2026, he acquired 7 shares of MetLife common stock at $85.57 per share through a grant tied to the MetLife Deferred Compensation Plan for Non-Management Directors. After this award, he holds 2,108 shares directly and 198 shares indirectly in a GRAT.
MetLife Inc. director Robert Glenn Hubbard acquired 678 shares of Common Stock as a compensation-related award. The shares were credited on June 9, 2026 at $85.57 per share as an imputed reinvestment of dividends on deferred shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
After this transaction, Hubbard directly holds 106,557 MetLife common shares. The filing characterizes the event as a grant or award, not an open-market purchase.
MetLife Inc. reported that President, U.S. Business Ramy Tadros acquired 127 shares of common stock on June 9, 2026. The shares were credited at an imputed price of $85.57 per share through reinvested dividends in the MetLife Leadership Deferred Compensation Plan, increasing his direct holdings to 216,946 shares. This reflects routine compensation-related accrual rather than an open-market purchase.
MetLife EVP & Chief Risk Officer Marlene Debel reported option exercises and share sales in common stock. On June 1, 2026, she exercised employee stock options to acquire 10,712 shares at $45.50 and 10,600 shares at $46.85 per share. The same day, she completed an open‑market sale of 21,312 shares at a weighted average price of $81.5889, with individual trade prices between $81.57 and $81.65. Following these transactions, she directly owns 154,380 shares of MetLife common stock.
MetLife Inc. EVP & Chief Accounting Officer Adrienne Karen O'Neill received a grant of 12,485 shares of Common Stock on April 30, 2026. The award is described as a restricted stock unit grant under the MetLife, Inc. 2025 Stock and Incentive Compensation Plan. Following this compensation-related acquisition, she directly holds 27,042 shares.
Harris Carla A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carla A. Harris received an award of 721 shares of common stock as part of non-management director compensation. The shares were valued at $71.17 each and are being deferred under the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, Harris directly holds 10,485 shares of MetLife common stock.
Seitz Michelle reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Michelle Seitz received a grant of 721 shares of Common Stock as part of her board compensation. The shares were awarded at a stated price of $0.00 per share as a non-management director retainer paid in MetLife common stock. Following this award, she holds 994 shares directly.
Kennard William E reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director William E. Kennard received a grant of 721 shares of MetLife common stock on April 1, 2026, as part of non‑management director compensation. The shares were valued at $71.17 each and he elected to defer receipt under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Kennard is reported as beneficially owning 46,501 shares of MetLife common stock directly, and an additional 10 shares are held indirectly in the MetLife Policyholder Trust that holds stock allocated to eligible policyholders.
HUBBARD ROBERT GLENN reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Robert Glenn Hubbard received a grant of 1,248 shares of common stock valued at $71.17 per share as part of non-management director compensation. This award reflects retainer fees that are paid in MetLife stock rather than cash.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the shares are credited rather than immediately delivered. Following this grant, he holds 105,878 shares of MetLife common stock directly.
MORRISON DENISE M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Denise M. Morrison received a grant of 721 shares of MetLife common stock on 2026-04-01 as part of non-management director compensation arrangements. The shares were awarded at $0.00 per share, reflecting stock-based fees rather than a market purchase.
After this award, Morrison directly holds 34,711 shares of MetLife common stock. A portion of MetLife’s non-management director retainer fees is paid in common stock, so this transaction represents routine equity compensation rather than an open-market trade.
Mumenthaler Christian Stephane reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Christian Stephane Mumenthaler received an equity grant of MetLife common stock as part of his board compensation. On this Form 4, he was awarded 721 shares of common stock at $71.17 per share, increasing his directly reported holdings to 2,846 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock and that he elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the compensation is taken in stock units rather than immediate cash.